Fig. 7

Validation of HCC EV TR Scores for differentiating post-Tx viable and post-Tx nonviable HCC in the validation set (n = 51). A Ladder plots summarizing the paired pre-Tx and post-Tx HCC EV Digital Scores for 34 post-Tx viable HCC patients and 17 post-Tx nonviable HCC patients. B Boxplots summarizing ∆ HCC EV Digital Scores for the 34 post-Tx viable HCC and 17 post-Tx nonviable HCC patients. C Boxplots showing the HCC EV TR Scores of the post-Tx viable and post-Tx nonviable HCC. The dashed line indicates the optimal cutoff of 0.76, calculated in the training set. D ROC curve of HCC EV TR Score for differentiating post-Tx viable HCC from post-Tx nonviable HCC in the validation set. E ROC curves of HCC EV TR Score, post-Tx serum AFP, and ∆ AFP in the combined training and validation set (98 patients with serum AFP data available). P = 0.0002 compared with post-Tx AFP and P < 0.0001 compared with ∆AFP using the paired DeLong’s test. AUROC, area under receiver operating characteristic curve; EV, extracellular vesicle; HCC, hepatocellular carcinoma; TR, treatment response; Tx, treatment